Related Experiment Video
Updated: May 8, 2026
The Galleria mellonella Waxworm Infection Model for Disseminated Candidiasis
Published on: November 17, 2018
Using Galleria mellonella-Candida albicans infection model to evaluate antifungal agents
De-Dong Li1, Li Deng, Gan-Hai Hu
1New Drug Research and Development Center, School of Pharmacy, Second Military Medical University.
Abstract:
Candida albicans is the most common fungal pathogen. Galleria mellonella is widely used as an infection model host. Nevertheless, the G. mellonella-C. albicans infection model had not been optimized for drug evaluation before this study. In this work, we revealed that 5 × 10(5) colony forming unit (CFU)/larva was a suitable inoculum to optimize the G. mellonella-C. albicans infection model in order to evaluate antifungal agents. Using our optimized model, the antifungal effect of fluconazole, amphotericin B and flucytosine, and the synergy between amphotericin B and flucytosine were successfully verified. Thus, this study provides a rapid, inexpensive and reliable way to evaluate antifungals in vivo.
Insights
This study optimized the Galleria mellonella-Candida albicans infection model for antifungal drug evaluation. The refined model successfully verified the efficacy of fluconazole, amphotericin B, and flucytosine in vivo.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Candida albicans is a prevalent fungal pathogen.
- Galleria mellonella larvae serve as a common infection model.
- The G. mellonella-C. albicans model lacked optimization for antifungal drug screening.
Purpose of the Study:
- To optimize the Galleria mellonella-C. albicans infection model for evaluating antifungal agents.
- To establish a reliable in vivo method for drug assessment.
Main Methods:
- Determined an optimal inoculum of 5 × 10(5) colony forming units (CFU)/larva.
- Utilized the optimized model to test antifungal drugs.
Main Results:
- Successfully verified the antifungal effects of fluconazole, amphotericin B, and flucytosine.
- Demonstrated the synergistic effect of amphotericin B and flucytosine combination therapy.
- Validated the optimized model's reliability for drug evaluation.
Conclusions:
- The optimized G. mellonella-C. albicans model offers a rapid, cost-effective, and dependable platform for in vivo antifungal agent evaluation.
- This model facilitates preclinical assessment of novel and existing antifungal therapies.
